Nuvalent, Inc. – NASDAQ:NUVL
Founder-led company
Nuvalent stock price today
$75
-5.29
-6.6%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Nuvalent stock price monthly change
+2.10%
month
Nuvalent stock price quarterly change
+2.10%
quarter
Nuvalent stock price yearly change
+7.54%
year
Nuvalent key metrics
Market Cap | 5.94B |
Enterprise value | N/A |
P/E | -18.38 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 3.10 |
PEG ratio | -0.81 |
EPS | -2.41 |
Revenue | N/A |
EBITDA | -171.87M |
Income | -145.50M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNuvalent stock price history
Nuvalent stock forecast
Nuvalent financial statements
Average Price Target
$114.8
Potential upside: 53.06%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -29.09M | |
|---|---|---|---|
| Sep 2023 | 0 | -33.64M | |
| Dec 2023 | 0 | -38.29M | |
| Mar 2024 | 0 | -44.48M |
| 2023-11-14 | -0.59 | -0.59 |
|---|---|---|
| 2024-02-27 | -0.59 | -0.62 |
| 2024-05-09 | -0.67 | -0.69 |
| Jun 2023 | 441948000 | 20.79M | 4.71% |
|---|---|---|---|
| Sep 2023 | 425080000 | 29.10M | 6.85% |
| Dec 2023 | 732384000 | 31.82M | 4.35% |
| Mar 2024 | 708466000 | 33.42M | 4.72% |
| Jun 2023 | -22.13M | 1.59M | 1.29M |
|---|---|---|---|
| Sep 2023 | -22.98M | 38.4M | 2.14M |
| Dec 2023 | -30.20M | -56.26M | 333.42M |
| Mar 2024 | -36.08M | -206.77M | 5.98M |
Nuvalent alternative data
| Aug 2023 | 70 |
|---|---|
| Sep 2023 | 78 |
| Oct 2023 | 78 |
| Nov 2023 | 78 |
| Dec 2023 | 89 |
| Jan 2024 | 89 |
| Feb 2024 | 89 |
| Mar 2024 | 92 |
| Apr 2024 | 92 |
| May 2024 | 92 |
| Jun 2024 | 106 |
| Jul 2024 | 106 |
Nuvalent other data
27.61%
-72.39%
of NUVL is owned by hedge funds
47
-47
13.71M
-39.18M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 974833 |
| Apr 2024 | 0 | 197500 |
| May 2024 | 0 | 83000 |
| Aug 2024 | 0 | 33500 |
| Sep 2024 | 0 | 60795 |
| Oct 2024 | 0 | 1044000 |
| Nov 2024 | 0 | 44000 |
| Dec 2024 | 0 | 1277000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BALCOM ALEXANDRA officer: Chief Financial Officer | Stock Option (Right to Buy) | 4,728 | $1.08 | $5,106 | ||
Option | BALCOM ALEXANDRA officer: Chief Financial Officer | Stock Option (Right to Buy) | 8,972 | $6.89 | $61,817 | ||
Option | BALCOM ALEXANDRA officer: Chief Financial Officer | Class A Common Stock | 8,972 | $6.89 | $61,817 | ||
Option | BALCOM ALEXANDRA officer: Chief Financial Officer | Class A Common Stock | 4,728 | $1.08 | $5,106 | ||
Option | PELISH HENRY E. officer: Chief Scientific Officer | Class A Common Stock | 4,500 | $0.87 | $3,915 | ||
Option | PELISH HENRY E. officer: Chief Scientific Officer | Class A Common Stock | 5,914 | $0.65 | $3,844 | ||
Option | PELISH HENRY E. officer: Chief Scientific Officer | Stock Option (Right to Buy) | 4,500 | $0.87 | $3,915 | ||
Option | PELISH HENRY E. officer: Chief Scientific Officer | Stock Option (Right to Buy) | 5,914 | $0.65 | $3,844 | ||
Option | PORTER JAMES RICHARD director, officer.. | Stock Option (Right to Buy) | 27,000 | $27.85 | $751,950 | ||
Option | PORTER JAMES RICHARD director, officer.. | Class A Common Stock | 27,000 | $27.85 | $751,950 |
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Nuvalent: Making Precise Progress In Its Oncology Pipeline
Nuvalent: NVL-655 Could Bring Blockbuster Potential
Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge
Nuvalent Looks Overvalued After A Rapid Rally
MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An Edge
MDA Breakout Stocks Week 49 - December 2022: Short-Term Picks To Give You An Edge
MDA Breakout Stocks Week 48 - December 2022: Short-Term Picks To Give You An Edge
-
What's the price of Nuvalent stock today?
One share of Nuvalent stock can currently be purchased for approximately $75.
-
When is Nuvalent's next earnings date?
Unfortunately, Nuvalent's (NUVL) next earnings date is currently unknown.
-
Does Nuvalent pay dividends?
No, Nuvalent does not pay dividends.
-
How much money does Nuvalent make?
Nuvalent has a market capitalization of 5.94B. Nuvalent made a loss 126.22M US dollars in net income (profit) last year or -$0.69 on an earnings per share basis.
-
What is Nuvalent's stock symbol?
Nuvalent, Inc. is traded on the NASDAQ under the ticker symbol "NUVL".
-
What is Nuvalent's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Nuvalent?
Shares of Nuvalent can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Nuvalent's key executives?
Nuvalent's management team includes the following people:
- Dr. James R. Porter Ph.D. Chief Executive Officer, Pres & Director(age: 50, pay: $451,880)
- Prof. Matthew D. Shair Ph.D. Founder, Head of Scientific Advisory Board & Director(age: 57, pay: $200,000)
-
Is Nuvalent founder-led company?
Yes, Nuvalent is a company led by its founder Prof. Matthew D. Shair Ph.D..
-
How many employees does Nuvalent have?
As Jul 2024, Nuvalent employs 106 workers, which is 15% more then previous quarter.
-
When Nuvalent went public?
Nuvalent, Inc. is publicly traded company for more then 4 years since IPO on 29 Jul 2021.
-
What is Nuvalent's official website?
The official website for Nuvalent is nuvalent.com.
-
Where are Nuvalent's headquarters?
Nuvalent is headquartered at One Broadway, Cambridge, MA.
-
How can i contact Nuvalent?
Nuvalent's mailing address is One Broadway, Cambridge, MA and company can be reached via phone at 857 357 7000.
-
What is Nuvalent stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Nuvalent in the last 12 months, the avarage price target is $114.8. The average price target represents a 53.06% change from the last price of $75.
Nuvalent company profile:
Nuvalent, Inc.
nuvalent.comExchange:
NASDAQ
Full time employees:
127
Industry:
Biotechnology
Sector:
Healthcare
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
One Broadway
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001861560
ISIN: US6707031075
CUSIP: 670703107
